Since its creation in 1992, ELA has forged special ties with Nathalie Cartier and has strongly supported her work. She participated in several events to support the actions of ELA and was a member of the Scientific Committee of ELA International from 2018 to 2022.
At a time when gene therapy was just beginning to show results in human, it was with the support of ELA and in collaboration with Pr. Patrick Aubourg that she worked on the ambitious project of a gene therapy for the treatment of the most severe form of Adrenoleukodystrophy, the cerebral form, in replacing the muted gene with a functional normal gene. The success of this work, published in 2009 and her expertise leaded her to become the president of the French Society for Cell and Gene Therapy until 2014 (SFTCG), and the president of the European Society of Cell and Gene Therapy until 2016.
Dr. Nathalie Cartier-Lacave is a world-renowned expert in the field of gene therapy and viral vectors. She was Director of Research at the National Institute of Health and Medical Research (INSERM), and, until 2022, led a team at the Brain Institute (ICM) at the Salpêtrière hospital in Paris. She has received many awards of excellence for her work (French Academy of Medicine Award, French Academy of Sciences Award, Jean Valade Foundation of France Award, and the Prize from the French Foundation for Medical Research), and was made a French Knight of the Legion of Honour for her services in the field of human health.
She joined AskBio as full-time Vice President of Neurobiology, and consequently leaves on the Scientific Committee of ELA International. Our collaboration could take other forms.
We would like to thank her warmly for her involvement in the research of innovative treatments against leukodystrophies, and for her participation in the Scientific Committee of ELA.
